Scorpion Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.scorpiontx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Phase 1
Recruiting
- Conditions
- EGFR/HER2 Exon 20 Insertion MutationNon-Small Cell Lung CancerNSCLC
- Interventions
- Drug: STX-721 (RP2D)Drug: STX-721 (Escalated)Drug: STX-721 (3 dose levels)
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Antares Therapeutics, Inc
- Target Recruit Count
- 185
- Registration Number
- NCT06043817
- Locations
- 🇫🇷
EDOG Institut de Cancerologie de l'Ouest - PPDS, Saint-Herblain, Loire-Atlantique, France
🇪🇸Hospital Regional Universitario de Malaga - Hospital General, Málaga, Malaga, Spain
🇺🇸City of Hope, Irvine, California, United States
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Breast CancerSolid Tumors, Adult
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Scorpion Therapeutics, Inc.
- Target Recruit Count
- 720
- Registration Number
- NCT05768139
- Locations
- 🇺🇸
Providence Cancer Institute, Portland, Oregon, United States
🇺🇸Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
News
No news found